Two-drug combo for hard-to-treat ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new combination of two medications for ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow the disease down in patients who have limited options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have a specific type of ovarian cancer (high-grade serous) that has come back, and it is resistant to platinum-based chemo (it progressed within 6 months of your last platinum treatment).
- Your tumor must test positive for a marker called FRα, which is a protein on the cancer cells that the study drug targets.
- You have had 1 to 3 previous lines of cancer treatment, and you have also had a treatment called bevacizumab (Avastin) before.
- You are generally in good health (able to take care of yourself, but not necessarily fully active) and have at least one measurable tumor that can be tracked on scans.
- You have no major eye problems, recent stroke, or bowel blockage, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This study tests a drug called mirvetuximab soravtansine (MIRV) for women with ovarian, fallopian tube, or primary peritoneal cancer that has not responded to recent treatment. The drug targets a specific protein (FRα) found on some cancer cells, and the study will see how well it works in real-world settings.
This study is testing a drug called mirvetuximab soravtansine (MIRV) in real-world conditions for people with a specific type of ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see how well the drug works and what side effects occur in everyday practice.
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
Hear when a new PROC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.